Quark Pharmaceuticals: Silence Therapeutics : Licensee Quark Pharmaceuticals Patient Dosed Ph 3

Quark Pharmaceuticals: Quark Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 14032018 Prices from USD $250

Quark Pharmaceuticals: Quark Pharmaceuticals Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 28112017 Prices from USD $250

Quark Pharmaceuticals: RiboQuark Pharmaceutical Technology Co. Ltd. Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI1007

Quark Pharmaceuticals: Quark Pharmaceuticals, Inc. to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference

Quark Pharmaceuticals: Quark Pharmaceuticals, Inc. Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting

Press Release: Quark Pharmaceuticals : Quark Pharmaceuticals, Inc. to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th Annual RNAi China Conference